Skip to main content
American Journal of Alzheimer's Disease and Other Dementias logoLink to American Journal of Alzheimer's Disease and Other Dementias
. 2005 Jul-Aug;20(4):233–238. doi: 10.1177/153331750502000408

Emotional reactions to predictive testing in Alzheimer's disease and other inherited dementias

José L Molinuevo, Luis Pintor, Josep Mª Peri 1, Alberto Lleó 2, Rafael Oliva 3, Teodor Marcos 4, Rafael Blesa 5
PMCID: PMC10833295  PMID: 16136847

Abstract

This work describes the reasons and emotional responses of healthy descendants after counseling for presenilin mutations in early-onset familial Alzheimer's disease (EOFAD), tau mutations in familial frontotemporal dementia (FTD), and prion mutations in fatal familial insomnia (FFI).

A multidisciplinary protocol following Huntington's disease counseling guidelines and a post-test follow-up program were developed to counsel healthy descendants of affected families. The psychological consequences, anxiety levels, and depression status were assessed through validated scales before and after disclosing the information.

Nine people from three different families, one with EOFAD, another with FTD, and the other with FFI came for counseling. Their main reason for testing was to initiate early treatment in the future. Disclosing the information decreased anxiety in two carriers, increased it temporarily in one, and had no effect in another. All noncarriers felt relieved. Overall, after a mean of 30 months of follow-up, no negative psychological reactions were observed. All participants positively valued the program.

Although preliminary, our observations suggest that predictive testing in EOFAD, FTD, and FFI is safe and may be of benefit when performed with a delicate approach under strict pretest counseling protocols and post-test follow-up programs. The emotional reactions were similar, although the diseases, their phenotype, and mutation characteristics were different.

Keywords: Alzheimer's disease, genetics, presenilin mutation, tau mutation, prion mutation, genetic counseling

Full Text

The Full Text of this article is available as a PDF (129.3 KB).

Contributor Information

Josep Mª Peri, Unidad Memoria-Alzheimer, Institut Clínic de Neurociencies, Hospital Clínic i Universitari, Barcelona, Spain..

Alberto Lleó, Servicio de Neurología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain..

Rafael Oliva, Servicio de Genética, Hospital Clínic i Universitari, Barcelona, Spain..

Teodor Marcos, Unidad Memoria-Alzheimer, Institut Clínic de Neurociencies, Hospital Clínic i Universitari, Barcelona, Spain..

Rafael Blesa, Servicio de Neurología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain..

References

  1. Goate A, Chartier-Harlin MC, Mullan M, et al.: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991; 349: 704-706. [DOI] [PubMed] [Google Scholar]
  2. Hutton M, Lendon CL, Rizzu P, et al.: Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998; 393: 702-705. [DOI] [PubMed] [Google Scholar]
  3. Medori R, Tritschler HJ, LeBlanc A, et al.: Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. New Engl J Med. 1992; 326: 444-449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Lannfelt L, Axelman K, Lilius L, et al.: Genetic counselling in a Swedish Alzheimer family with amyloid precursor protein mutation. Am J Hum Genet. 1995; 56: 332-335. [PMC free article] [PubMed] [Google Scholar]
  5. Wiggins S, Whyte P, Huggins M, et al.: The psychological consequences of predictive testing for Huntington's disease. New Engl J Med. 1992; 327: 1401-1405. [DOI] [PubMed] [Google Scholar]
  6. Goldman JS, Hou CE: Early-onset Alzheimer disease: When is genetic testing appropriate? Alzheimer Dis Assoc Disord. 2004; 18: 65-67. [DOI] [PubMed] [Google Scholar]
  7. Fox S, Bloch M, Fahy M, et al.: Predictive testing in Huntington's disease. Description of a pilot project in British Columbia. Am J Med Genet. 1989; 32: 211-216. [DOI] [PubMed] [Google Scholar]
  8. First MB, Spitzer RL, Gibbon M, et al.: Structured Clinical Interview for DSM-IV Axis I Disorders—Clinician Version (SCID-CV). Washington, DC: American Psychiatry Association Press, Inc., 1997. [Google Scholar]
  9. Lleo A, Blesa R, Queralt R, et al.: Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain. Arch Neurol. 2002; 59: 1759-1763. [DOI] [PubMed] [Google Scholar]
  10. Herrero MJ, Torres X, Blanch J, et al.: A validation study of the Hospital anxiety and depression scale (HADS) in a Spanish population. Gen Hosp Psychiatry. 2003; 25: 277-283. [DOI] [PubMed] [Google Scholar]
  11. Steinbart EJ, Smith CO, Poorkaj P, et al.: Impact of DNA testing for early onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol. 2001; 58: 1828-1831. [DOI] [PubMed] [Google Scholar]
  12. Adam S, Wiggins S, Whyte P, et al.: Five year study of prenatal testing for Huntington's disease: Demand, attitudes, and psychological assessment. J Med Genet. 1993; 30: 549-556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Broadstock M, Michie S, Marteu T: The psychological consequences of predictive genetic testing: A recent systematic review. Eur J Hum Genet. 2000; 8: 731-738. [DOI] [PubMed] [Google Scholar]
  14. Beauchamp TL, Childress J: Principles of Biomedical Ethics. New York: Oxford University Press, 2001: Chapter 3. [Google Scholar]

Articles from American Journal of Alzheimer's Disease and Other Dementias are provided here courtesy of SAGE Publications

RESOURCES